Skip to main content

Table 2 Changes in blood pressure and heart rate

From: Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

  Dapagliflozin Exenatide Dapagliflozin + exenatide Placebo
1.5 weeks 16 weeks 1.5 weeks 16 weeks 1.5 weeks 16 weeks 1.5 weeks 16 weeks
Blood pressure and heart rate
SBP (mmHg)
 Within groups − 4.7 ± 2.1* − 4.4 ± 2.7 − 0.6 ± 1.7 − 1.3 ± 2.1 − 4.2 ± 1.9* − 6.8 ± 2.4* − 0.9 ± 2.3 − 1.4 ± 2.4
 Between groups − 4.5 ± 2.9 − 1.8 ± 3.0 0.45 ± 2.8 0.5 ± 2.8 − 6.4 ± 3.0* − 6.7 ± 3.1*   
 DBP (mmHg) − 1.5 ± 1.8 0.5 ± 1.8 − 0.1 ± 1.7 1.8 ± 1.8 − 2.3 ± 1.9 − 1.7 ± 1.9   
 Heart rate (bpm) 0.2 ± 2.8 2.4 ± 2.8 3.9 ± 2.7 3.0 ± 2.8 3.4 ± 2.9 3.2 ± 2.9   
  1. Linear mixed models were used to compare baseline corrected treatment effects with placebo (mean ± SE). For systolic blood pressure, within group differences and between group differences are displayed
  2. *P < 0.05 for differences in change during treatments compared with placebo
  3. SBP, systolic blood pressure; DBP diastolic blood pressure